Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
207 hedge funds and large institutions have $479M invested in Esperion Therapeutics in 2026 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 65 increasing their positions, 60 reducing their positions, and 31 closing their positions.
346% more call options, than puts
Call options by funds: $11.5M | Put options by funds: $2.57M
185% more capital inflows, than outflows
Capital inflows: $184M | Capital outflows: $64.8M
32% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 31
4.81% more ownership
Funds ownership: 63.28% → 68.09% (+4.8%)
3% more funds holding
Funds holding: 201 → 207 (+6)
8% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 60
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$20M |
| 2 |
Two Sigma Investments
New York
|
+$14.9M |
| 3 |
O
OrbiMed
New York
|
+$14.6M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$12.6M |
| 5 |
AC
Armistice Capital
New York
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$10.5M |
| 2 |
EP
Eversept Partners
New York
|
-$6.7M |
| 3 |
Walleye Capital
New York
|
-$4.96M |
| 4 |
RA
Royce & Associates
New York
|
-$3.09M |
| 5 |
Jane Street
New York
|
-$3.03M |
ESPR Hedge Fund Activity: Q1 2026 in Review
207 of the 8,210 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q1 2026, worth a combined $479M — down 14% from $560M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new ESPR positions and 31 closed out — a net gain of 10 holders — while 65 added to existing stakes and 60 trimmed.
The largest buyer was Wasatch Advisors, adding an estimated $20M. The largest seller was Millennium Management, cutting an estimated $10.5M.
- 207 institutional investors held Esperion Therapeutics (ESPR) as of Q1 2026, up from 201 in Q4 2025.
- Funds reported $479M of Esperion Therapeutics stock for Q1 2026, down 14% quarter-over-quarter.
- 41 funds opened new Esperion Therapeutics positions in Q1 2026 and 31 closed out, a net change of +10 holders.
- The largest Esperion Therapeutics buyer in Q1 2026 was Wasatch Advisors, an estimated $20M added.
- The largest Esperion Therapeutics seller in Q1 2026 was Millennium Management, an estimated $10.5M sold.
Based on aggregated 13F filings for Q1 2026.